NCT02568449View on ClinicalTrials.gov

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

January 1, 2017

Study Completion Date

June 26, 2018

Conditions
Recurrent Pleural Malignant MesotheliomaStage IV Pleural Mesothelioma
Interventions
DRUG

Nintedanib

Given PO

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02568449 - Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | Biotech Hunter | Biotech Hunter